SANOFI |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89.32 EUR | +0.17% |
|
-3.69% | -0.52% |
| 02:52pm | Shah Capital ends campaign against Novavax board after Sanofi deal | RE |
| 12:36pm | Shah Capital withdraws campaign against Novavax directors after Sanofi deal | RE |
Presenter SpeechSerge Weinberg (Executives)Ladies and gentlemen, good afternoon. We brought yo...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows:
- pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases);
- human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas;
- consumer health products (12%).
At the end of 2023, the group had 54 production sites throughout the world.
Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
89.17
EUR
Average target price
108.3
EUR
Spread / Average Target
+21.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.52% | 121B | |
| +33.48% | 693B | |
| +29.39% | 584B | |
| -2.65% | 372B | |
| +20.64% | 332B | |
| +6.99% | 294B | |
| +14.02% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +9.13% | 168B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Transcript : Sanofi - Shareholder/Analyst Call
